Belkys S, Marrero MT, Oliva JP, Martínez AÍ, Velasco M

Language: Spanish
References: 20
Page: 52-56
PDF size: 61.55 Kb.

ABSTRACT

The thyroid cancer constitutes the endocrinology neoplasia the most frequency. The human thyroglobulin is the main tumor marker during the postoperative follow-up of patients presenting with thyroid differentiated cancer. The previous premise is valid if don’t exist thyroglobulin antibodies that can interfere in its quantification, being this the analytic main problem that involve the utility of the thyroglobulin like tumor marker and that it limits its clinical utility. One hundred patients were studied assisted in the thyroid surgery of the National Institute of Oncology and Radiobiology to who you practiced total thyroidectomy to present differentiated cancer of thyroid. 83 women and 14 men were included in this study (half age of 45.1 ± 11.2 years). They were assessment the thyroglobulin levels and of thyroglobulin antibodies in serum, using for it two different methods immunometrics; Immunoradiometric method and radioimmunoassay respectively. We studied the interference that provokes the thyroglobulin antibodies in the quantification of thyroglobulin during the postoperative follow-up of patients presenting with thyroid differentiated cancer. The recovery test does not provide reliable information of the interference of antithyroglobulin autoantibodies in the determination of thyroglobulin.
For all blood samples sent to the laboratory for determination of thyroglobulin, they should also perform quantization of antithyroglobulin autoantibodies interference. With the results, a protocol should be established for monitoring patients operated for differentiated thyroid carcinoma.

REFERENCES

1. Spencer C. Thyroglobulin. In: Werner SC, Ingbar SH, Braverman LE, Utiger RD. Werner and Ingbar’s. The Thyroid: A fundamental and clinical text. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005: 345-353.

2. Van de Graff Sar, Ris-Stalpers C, Pauws E,Mendive FM. Up to date with human thyroglobulin. J Endocrinol 2001; 170: 307-321.

3. Mazzaferri E, Robbins R, Spencer A. Consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 1433-1434.

4. Spencer CA. Serum thyroglobulin measurements: climical utility and technical limitations in the management of patients with differentiated thyroid carcinoma. Endocrine Practice 2000; 6: 481-484.

5. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, GuttlerRB, Singer PA et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121-1127.

6. Spencer CA, Bergoglio LM, Kazarosyan M. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005; 90: 5566-5575.

7. Spencer CA, LoPresti JS. Technology Insight: Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Available in: http://www.nature.com/clinicalpractices/endmel (Access: Abril, 2008).

8. Demers LM, Spencer CA. Laboratory support for the diagnosis and monitoring of thyroid disease. The National Academy of Clinical Biochemistry Laboratory Medicine. Practice Guidelines. Available in: http://www.nacb.org/lmpg/thyroid/LMPG/Wordstm 2002 (Access: February, 2008).

9. Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical, benefits and pitfalls. Thyroid Cancer I. Endocrinol Metabol Clin North Ame 1995; 24: 841-863.

10. Hjiyiannakis P, Mundy J, Harmer C. Thyroglobulin antibodies in differentiated thyroid cancer. Clin Oncol 1999; 11: 240-244.

11. Cooper DS, Doherty GM,Hagen BR, Kloos RT, Lee SL, Mandel SJ et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association Guidelines Taskforce. Thyroid 2006; 16: 109-142.

12. Schlumberger M, Benhamou F. Comparison of seven srum Thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007; 92: 2487-2495.

13. Chiovato L, Latrofa F, Braverman LE, Pacini F et al. Disappearense of humoral thyroid autoimmunity after complete removal of thyroid anteigens. Ann Intern Med 2003; 139: 346-351.

14. Phan HTT, Jager PL, Van der Wal JE et al. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol 2008; 158: 77–83.

15. Matsubayashi S, Kawai K, Matsumoto Y. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 1995; 80: 3421-3424.

16. Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. Clin Chem 1996; 42: 661-663.

17. Massart C, Maugendre D. Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves’ disease. Clin Chem 2002; 48: 102-107,319.

18. Mariotti S, Barbesino G, Caturegli P, Marino M, Manetti L, Pacini F et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? J Clin Endocrinol Metab 1995; 80.

19. Schulz R, Bethauser H, Stempka L, Heilig B, Moll A, Hufner M. Evidence for immunological differences between circulating and tissue-derived thyroglobulin in men. Eur J Clin Invest 1989; 19: 459-463.

20. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996; 42: 164-173.